ProCE Banner Activity

Venetoclax Monotherapy for Relapsed/Refractory MM: Phase I Results

Slideset Download
Conference Coverage
Venetoclax was safe and tolerable in heavily pretreated patients with myeloma with an ORR of 40% in patients with t(11;14) translocation.

Released: December 07, 2016

Expiration: December 06, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Seagen